Epidiolex liver check: no alarm, just monitoring
NCT ID NCT05044819
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study watches for possible long-term liver damage in 154 people already taking or starting Epidiolex for certain seizure disorders. Researchers will use blood tests and special scans to check for liver scarring over time. The goal is to understand if the drug can cause chronic liver injury, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LENNOX GASTAUT SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Little Rock, Arkansas, 72758, United States
-
Clinical Trial Site
Downey, California, 90242, United States
-
Clinical Trial Site
Long Beach, California, 90806, United States
-
Clinical Trial Site
Sacramento, California, 95817, United States
-
Clinical Trial Site
Miami, Florida, 33136, United States
-
Clinical Trial Site
Miami, Florida, 33176, United States
-
Clinical Trial Site
Orlando, Florida, 32806, United States
-
Clinical Trial Site
Tampa, Florida, 33606, United States
-
Clinical Trial Site
Augusta, Georgia, 30912, United States
-
Clinical Trial Site
Wichita, Kansas, 67214, United States
-
Clinical Trial Site
Lexington, Kentucky, 40504, United States
-
Clinical Trial Site
Baltimore, Maryland, 21205, United States
-
Clinical Trial Site
Boston, Massachusetts, 02114, United States
-
Clinical Trial Site
New Brunswick, New Jersey, 08901, United States
-
Clinical Trial Site
New York, New York, 10016, United States
-
Clinical Trial Site
Charlotte, North Carolina, 28203, United States
-
Clinical Trial Site
Durham, North Carolina, 27708, United States
-
Clinical Trial Site
Cincinnati, Ohio, 45219, United States
-
Clinical Trial Site
Oklahoma City, Oklahoma, 73104, United States
-
Clinical Trial Site
Philadelphia, Pennsylvania, 19107, United States
-
Clinical Trial Site
Charleston, South Carolina, 29425, United States
-
Clinical Trial Site
Austin, Texas, 78758, United States
-
Clinical Trial Site
Dallas, Texas, 75251, United States
-
Clinical Trial Site
Houston, Texas, 77030, United States
-
Clinical Trial Site
Round Rock, Texas, 78681, United States
-
Clinical Trial Site
Winchester, Virginia, 22601, United States
Conditions
Explore the condition pages connected to this study.